中国实用医刊
中國實用醫刊
중국실용의간
Chinese Journal of Practical Medicine
2015年
22期
4-6
,共3页
石海洲%王笃杰%丁文贤%许传屾
石海洲%王篤傑%丁文賢%許傳屾
석해주%왕독걸%정문현%허전신
晚期乳腺癌%新辅助化疗%MicroRNA
晚期乳腺癌%新輔助化療%MicroRNA
만기유선암%신보조화료%MicroRNA
Advanced breast cancer%Neoadjuvant chemotherapy%MicroRNA
目的:分析新辅助化疗对晚期乳腺癌患者血浆microRNA及肿瘤相关指标的影响。方法收集晚期乳腺癌患者120例,随机分为新辅助化疗组( NC组)和常规化疗组( CC组),每组60例,分别纳入同时期良性乳腺病和健康志愿者各60例,作为良性对照组( BC组)和健康对照组( HC组)。对所有受试者血浆microRNA( miR-31、miR-200c、miR-205)和肿瘤相关指标[可溶性白细胞介素-2受体( sIL-2R)、白细胞介素-6( IL-6)、血管内皮生长因子( VEGF)]水平进行检测,比较组间差异。结果化疗前NC组和CC组血浆miR-31、miR-205表达水平显著低于良性乳腺病患者和健康志愿者,miR-200c、sIL-2R、IL-6和VEGF水平则显著高于BC组和HC组(P<0.05);晚期乳腺癌患者治疗效果与血浆miR-31、miR-205表达水平呈正相关,而与miR-200c、sIL-2R、IL-6和VEGF水平呈负相关。化疗后第15、45天,NC组血浆miR-31、miR-205表达水平显著高于CC组,miR-200c、sIL-2R、IL-6和VEGF水平则显著高于CC组( P<0.05)。结论新辅助化疗能有效上调晚期乳腺癌患者血浆miR-31、miR-205水平,下调miR-200c、sIL-2R、IL-6和VEGF水平,对晚期乳腺癌有改善作用。
目的:分析新輔助化療對晚期乳腺癌患者血漿microRNA及腫瘤相關指標的影響。方法收集晚期乳腺癌患者120例,隨機分為新輔助化療組( NC組)和常規化療組( CC組),每組60例,分彆納入同時期良性乳腺病和健康誌願者各60例,作為良性對照組( BC組)和健康對照組( HC組)。對所有受試者血漿microRNA( miR-31、miR-200c、miR-205)和腫瘤相關指標[可溶性白細胞介素-2受體( sIL-2R)、白細胞介素-6( IL-6)、血管內皮生長因子( VEGF)]水平進行檢測,比較組間差異。結果化療前NC組和CC組血漿miR-31、miR-205錶達水平顯著低于良性乳腺病患者和健康誌願者,miR-200c、sIL-2R、IL-6和VEGF水平則顯著高于BC組和HC組(P<0.05);晚期乳腺癌患者治療效果與血漿miR-31、miR-205錶達水平呈正相關,而與miR-200c、sIL-2R、IL-6和VEGF水平呈負相關。化療後第15、45天,NC組血漿miR-31、miR-205錶達水平顯著高于CC組,miR-200c、sIL-2R、IL-6和VEGF水平則顯著高于CC組( P<0.05)。結論新輔助化療能有效上調晚期乳腺癌患者血漿miR-31、miR-205水平,下調miR-200c、sIL-2R、IL-6和VEGF水平,對晚期乳腺癌有改善作用。
목적:분석신보조화료대만기유선암환자혈장microRNA급종류상관지표적영향。방법수집만기유선암환자120례,수궤분위신보조화료조( NC조)화상규화료조( CC조),매조60례,분별납입동시기량성유선병화건강지원자각60례,작위량성대조조( BC조)화건강대조조( HC조)。대소유수시자혈장microRNA( miR-31、miR-200c、miR-205)화종류상관지표[가용성백세포개소-2수체( sIL-2R)、백세포개소-6( IL-6)、혈관내피생장인자( VEGF)]수평진행검측,비교조간차이。결과화료전NC조화CC조혈장miR-31、miR-205표체수평현저저우량성유선병환자화건강지원자,miR-200c、sIL-2R、IL-6화VEGF수평칙현저고우BC조화HC조(P<0.05);만기유선암환자치료효과여혈장miR-31、miR-205표체수평정정상관,이여miR-200c、sIL-2R、IL-6화VEGF수평정부상관。화료후제15、45천,NC조혈장miR-31、miR-205표체수평현저고우CC조,miR-200c、sIL-2R、IL-6화VEGF수평칙현저고우CC조( P<0.05)。결론신보조화료능유효상조만기유선암환자혈장miR-31、miR-205수평,하조miR-200c、sIL-2R、IL-6화VEGF수평,대만기유선암유개선작용。
Objective To evaluate the effect of neoadjuvant chemotherapy on microRNA and tumor-related indicators in patients with advanced breast cancer.Methods One hundred and twenty pa-tients with advanced breast cancer were randomly divided into NC group and CC group with 60 cases in each group,and 60 patients with benign breast disease and 60 healthy volunteers in the same period were included as BC group and HC group.Then the plasma levels of miR-31, miR-200c, miR-205 and sIL-2R, IL-6, VEGF of all subjects were detected and compared.Results The plasma levels of miR-31 and miR-205 of NC group and CC group before treatment were lower than those of BC group and HC group, while the miR-200c and sIL-2R, IL-6, VEGF were higher than those of BC group and HC group( P<0.05 ) .The efficacy of treatment of advanced breast cancer patients was positively correlated to the plas-ma levels of miR-31, miR-205 expression, and negatively correlated to the plasma levels of miR-200c and sIL-2R, IL-6, VEGF.After 15, 45 days of chemotherapy, the plasma levels of miR-31, miR-205 expression of NC group were significantly higher than those of CC group, and miR-200c and sIL-2R, IL-6 , VEGF were significantly lower than those of CC group ( P <0.05 ) .Conclusions Neoadjuvant chemotherapy can effectively increase the plasma levels of miR-31, miR-205, and reduce the plasma lev-els of miR-200c and sIL-2R, IL-6, VEGF, so it is beneficial to improve the advanced breast cancer.